the pandemic of the Covid-19 (Corona virus)

message for all the patient organisations


The board of directors and the Amyloidosis Alliance staff, would like to express support for those individuals and families already directly affected by COVID-19 around the world.

European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

A decisive step has been taken in the Vyndaqel market access procedure for wild type and hereditary transthyretin amyloidosis cardiomyopathy

Good news for Brazil

Alnylam received market authorization for Patisiran in Brazil

Last week, Brazil obtained marketing authorization for Tafamidis for ATTR cardiomyopathy (ATTR-CM)

The refund approval process will begin now. It is important to note that in the past two months, Brazil has experienced 2 other important events.